Expanding the Clinical and Mutational Spectrum of Kaufman Oculocerebrofacial Syndrome with Biallelic UBE3B Mutations

Total Page:16

File Type:pdf, Size:1020Kb

Expanding the Clinical and Mutational Spectrum of Kaufman Oculocerebrofacial Syndrome with Biallelic UBE3B Mutations View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by RERO DOC Digital Library Hum Genet (2014) 133:939–949 DOI 10.1007/s00439-014-1436-2 ORIGINAL INVESTIGATION Expanding the clinical and mutational spectrum of Kaufman oculocerebrofacial syndrome with biallelic UBE3B mutations Lina Basel-Vanagaite · Rüstem Yilmaz · Sha Tang · Miriam S. Reuter · Nils Rahner · Dorothy K. Grange · Megan Mortenson · Patrick Koty · Heather Feenstra · Kelly D. Farwell Gonzalez · Heinrich Sticht · Nathalie Boddaert · Julie Désir · Kwame Anyane-Yeboa · Christiane Zweier · André Reis · Christian Kubisch · Tamison Jewett · Wenqi Zeng · Guntram Borck Received: 16 December 2013 / Accepted: 25 February 2014 / Published online: 11 March 2014 © Springer-Verlag Berlin Heidelberg 2014 Abstract Biallelic mutations of UBE3B have recently additional patients from five unrelated families using either been shown to cause Kaufman oculocerebrofacial syn- targeted UBE3B sequencing in individuals with sugges- drome (also reported as blepharophimosis–ptosis–intellec- tive facial dysmorphic features, or exome sequencing. Our tual disability syndrome), an autosomal recessive condition results expand the clinical and mutational spectrum of the characterized by hypotonia, developmental delay, intellec- UBE3B-related disorder in several ways. First, we have tual disability, congenital anomalies, characteristic facial identified UBE3B mutations in individuals who previously dysmorphic features, and low cholesterol levels. To date, received distinct clinical diagnoses: two sibs with Toriello– six patients with either missense mutations affecting the Carey syndrome as well as the patient reported to have a UBE3B HECT domain or truncating mutations have been “new” syndrome by Buntinx and Majewski in 1990. Sec- described. Here, we report on the identification of homozy- ond, we describe the adult phenotype and clinical variabil- gous or compound heterozygous UBE3B mutations in six ity of the syndrome. Third, we report on the first instance of homozygous missense alterations outside the HECT domain of UBE3B, observed in a patient with mildly dys- L. Basel-Vanagaite and R. Yilmaz contributed equally. morphic facial features. We conclude that UBE3B muta- tions cause a clinically recognizable and possibly under- Electronic supplementary material The online version of this diagnosed syndrome characterized by distinct craniofacial article (doi:10.1007/s00439-014-1436-2) contains supplementary material, which is available to authorized users. L. Basel-Vanagaite (*) M. S. Reuter · C. Zweier · A. Reis Raphael Recanati Genetic Institute and Felsenstein Medical Institute of Human Genetics, Friedrich-Alexander-Universität Research Center, Rabin Medical Center, Beilinson Campus, Erlangen-Nürnberg, 91054 Erlangen, Germany 49100 Petah Tikva, Israel e-mail: [email protected] N. Rahner Medical Faculty, Institute of Human Genetics, University L. Basel-Vanagaite of Dusseldorf, 40225 Dusseldorf, Germany Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel D. K. Grange Division of Genetics and Genomic Medicine, Department L. Basel-Vanagaite of Pediatrics, Washington University School of Medicine, Pediatric Genetics, Schneider Children’s Medical Center St. Louis Children’s Hospital, St. Louis, MO 63110, USA of Israel, 49202 Petah Tikva, Israel M. Mortenson · P. Koty · T. Jewett R. Yilmaz · C. Kubisch · G. Borck (*) Department of Pediatrics, Section on Medical Genetics, Wake Institute of Human Genetics, University of Ulm, Forest School of Medicine, Winston-Salem, NC 27157, USA 89081 Ulm, Germany e-mail: [email protected] H. Feenstra Roosevelt Hospital, New York, NY 10019, USA S. Tang · K. D. Farwell Gonzalez · W. Zeng Ambry Genetics, Aliso Viejo, CA 92656, USA 1 3 940 Hum Genet (2014) 133:939–949 features, hypotonia, failure to thrive, eye abnormalities, Silfhout et al. 2013), and Dubowitz syndrome (MIM other congenital malformations, low cholesterol levels, and 223370) (reviewed by Verloes et al. 2006). severe intellectual disability. We review the UBE3B-asso- Only six patients with KOS/BPID syndrome and bial- ciated phenotypes, including forms that can mimick Tori- lelic UBE3B mutations have been described previously ello–Carey syndrome, and suggest the single designation (Basel-Vanagaite et al. 2012; Flex et al. 2013). Here, we “Kaufman oculocerebrofacial syndrome”. describe six additional patients and review the clinical and molecular spectrum of this recognizable entity. Introduction Methods Kaufman oculocerebrofacial syndrome (KOS; MIM 244450) is an autosomal recessive disorder character- Patient ascertainment and clinical evaluations ized by developmental delay and intellectual disability (ID), microcephaly, hypotonia, structural eye anoma- The study was approved by the Ethics Committees of the lies and other organ malformations, as well as distinctive Universities of Ulm and Erlangen-Nürnberg, and written facial dysmorphic features. Fewer than 10 affected indi- informed consent was obtained from the patients’ parents viduals had been reported from the first description in or legal guardian. We report on six individuals from five 1971 to 2012 (Kaufman et al. 1971; Figuera et al. 1993; unrelated families. The affected individuals were evaluated Garcia-Cruz et al. 1988; Dentici et al. 2011) when we by routine medical history interviews and a physical exami- redescribed the syndrome (under the acronym BPID syn- nation, and clinical records were reviewed. All six patients drome, blepharophimosis–ptosis–intellectual disability had undergone brain imaging [magnetic resonance imaging syndrome; MIM 615057) and identified biallelic UBE3B (MRI) in patients 1-5 and computed tomography in patient mutations as the underlying cause (Basel-Vanagaite et al. 6], and the MRI scans were reviewed by one radiologist 2012). In that report, patients with BPID syndrome were (N.B.). A basic endocrinological evaluation had been per- thought to have a distinctive condition because they lacked formed in all affected individuals. the eye abnormalities characteristic to patients with KOS, In patients 1–3, KOS was not regarded as a differential such as microphthalmia and optic nerve anomalies. There diagnosis and mutations were identified following clinical is a phenotypic overlap between KOS, Toriello–Carey syn- diagnostic or research exome sequencing. After the reports drome (TCS; agenesis of the corpus callosum with facial on UBE3B mutations as the cause of KOS (Basel-Vanagaite anomalies and Pierre-Robin sequence; MIM 217980; Tori- et al. 2012; Flex et al. 2013) the attending geneticists of ello et al. 2003) and the phenotype reported by Buntinx patients 1–3 contacted L.B.-V. and G.B. UBE3B mutations and Majewski as a “new” syndrome in 1990 (Buntinx and were suspected in patients 4–6 based mainly on facial dys- Majewski 1990). The differential diagnosis of KOS and morphic features following a literature review performed related syndromes extends to other blepharophimosis– by one of the authors (L.B.-V.) although these three chil- intellectual disability syndromes (or Ohdo-like syndromes) dren had previously received clinical diagnoses different such as Ohdo syndrome (MIM 249620), KAT6B-associated from KOS/BPID. Patients 4 and 5 are siblings and have Say-Barber/Biesecker/Young-Simpson syndrome (MIM been reported with a diagnosis of typical TCS (Toriello 603736; Clayton-Smith et al. 2011), MED12-associated et al. 2003); and patient 6 was reported by Buntinx and Maat-Kievit-Brunner syndrome (MIM 300895; Vulto-van Majewski (1990). Exome and Sanger sequencing H. Sticht Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany UBE3B mutations were identified by whole exome sequencing in patients 1–3 and by Sanger sequencing of N. Boddaert the coding exons and exon–intron boundaries in patients Department of Pediatric Radiology, Hôpital Necker, Enfants 4–6. After the identification of a mutation in a sibling pair Malades and Medical Faculty, Université Paris Descartes, 75015 Paris, France with a previous diagnosis of TCS, we sequenced UBE3B in four additional unrelated patients with TCS, two of whom J. Désir have been reported previously (Toriello et al. 2003). Exome Institut de Pathologie et de Génétique, 6041 Gosselies, Belgium sequencing was performed using the SureSelect Human All Exon 50 Mb Kit (Agilent) and a paired-end proto- K. Anyane-Yeboa Columbia University Medical Center, New York, NY 10010, col on an Illumina HiSeq 2000 sequencer (patients 1 and USA 3) or a SOLiD 5500xl instrument (patient 2). Reads were 1 3 Hum Genet (2014) 133:939–949 941 Fig. 1 Facial features of the individuals described in this study. The numbers correspond to the numbers in Table 1. Ages of the patients are as follows: 1, 33 years; 2A, 8 months; 2B, 5 years 6 months; 3A, 4 months; 3B, 2 years; 4, 16 years; 5, 10 years 8 months; 6, 25 years aligned to the human genome assembly hg19 (GRCh37) Patient 1 (Fig. 1, picture 1; Table 1) is a 33-year-old man and variants were called and annotated using software inte- with profound ID and no speech. He is the second son (of grated in the respective in-house exome analysis pipeline three) born to unaffected parents of Hispanic ancestry who as described previously [Gandomi et al. 2013, for patients are second cousins once removed. He presented at birth 1 and 3; Hansen et al. 2013 (patient MR043), for patient with muscular hypotonia and hearing impairment. Unlike 2]. This resulted in a mean
Recommended publications
  • Circle Applicable Codes
    IDENTIFYING INFORMATION (please print legibly) Individual’s Name: DOB: Last 4 Digits of Social Security #: CIRCLE APPLICABLE CODES ICD-10 ICD-10 ICD-9 DIAGNOSTIC ICD-9 DIAGNOSTIC PRIMARY ICD-9 CODES CODE CODE PRIMARY ICD-9 CODES CODE CODE Abetalipoproteinemia 272.5 E78.6 Hallervorden-Spatz Syndrome 333.0 G23.0 Acrocephalosyndactyly (Apert’s Syndrome) 755.55 Q87.0 Head Injury, unspecified – Age of onset: 959.01 S09.90XA Adrenaleukodystrophy 277.86 E71.529 Hemiplegia, unspecified 342.9 G81.90 Arginase Deficiency 270.6 E72.21 Holoprosencephaly 742.2 Q04.2 Agenesis of the Corpus Callosum 742.2 Q04.3 Homocystinuria 270.4 E72.11 Agenesis of Septum Pellucidum 742.2 Q04.3 Huntington’s Chorea 333.4 G10 Argyria/Pachygyria/Microgyria 742.2 Q04.3 Hurler’s Syndrome 277.5 E76.01 or 758.33 Aicardi Syndrome 333 G23.8 Hyperammonemia Syndrome 270.6 E72.4 Alcohol Embryo and Fetopathy 760.71 F84.5 I-Cell Disease 272.2 E77.0 Anencephaly 655.0 Q00.0 Idiopathic Torsion Dystonia 333.6 G24.1 Angelman Syndrome 759.89 Q93.5 Incontinentia Pigmenti 757.33 Q82.3 Asperger Syndrome 299.8 F84.5 Infantile Cerebral Palsy, unspecified 343.9 G80.9 Ataxia-Telangiectasia 334.8 G11.3 Intractable Seizure Disorder 345.1 G40.309 Autistic Disorder (Childhood Autism, Infantile 299.0 F84.0 Klinefelter’s Syndrome 758.7 Q98.4 Psychosis, Kanner’s Syndrome) Biotinidase Deficiency 277.6 D84.1 Krabbe Disease 333.0 E75.23 Canavan Disease 330.0 E75.29 Kugelberg-Welander Disease 335.11 G12.1 Carpenter Syndrome 759.89 Q87.0 Larsen’s Syndrome 755.8 Q74.8 Cerebral Palsy, unspecified 343.69 G80.9
    [Show full text]
  • Level Estimates of Maternal Smoking and Nicotine Replacement Therapy During Pregnancy
    Using primary care data to assess population- level estimates of maternal smoking and nicotine replacement therapy during pregnancy Nafeesa Nooruddin Dhalwani BSc MSc Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy November 2014 ABSTRACT Background: Smoking in pregnancy is the most significant preventable cause of poor health outcomes for women and their babies and, therefore, is a major public health concern. In the UK there is a wide range of interventions and support for pregnant women who want to quit. One of these is nicotine replacement therapy (NRT) which has been widely available for retail purchase and prescribing to pregnant women since 2005. However, measures of NRT prescribing in pregnant women are scarce. These measures are vital to assess its usefulness in smoking cessation during pregnancy at a population level. Furthermore, evidence of NRT safety in pregnancy for the mother and child’s health so far is nebulous, with existing studies being small or using retrospectively reported exposures. Aims and Objectives: The main aim of this work was to assess population- level estimates of maternal smoking and NRT prescribing in pregnancy and the safety of NRT for both the mother and the child in the UK. Currently, the only population-level data on UK maternal smoking are from repeated cross-sectional surveys or routinely collected maternity data during pregnancy or at delivery. These obtain information at one point in time, and there are no population-level data on NRT use available. As a novel approach, therefore, this thesis used the routinely collected primary care data that are currently available for approximately 6% of the UK population and provide longitudinal/prospectively recorded information throughout pregnancy.
    [Show full text]
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature
    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
    [Show full text]
  • Soonerstart Automatic Qualifying Syndromes and Conditions
    SoonerStart Automatic Qualifying Syndromes and Conditions - Appendix O Abetalipoproteinemia Acanthocytosis (see Abetalipoproteinemia) Accutane, Fetal Effects of (see Fetal Retinoid Syndrome) Acidemia, 2-Oxoglutaric Acidemia, Glutaric I Acidemia, Isovaleric Acidemia, Methylmalonic Acidemia, Propionic Aciduria, 3-Methylglutaconic Type II Aciduria, Argininosuccinic Acoustic-Cervico-Oculo Syndrome (see Cervico-Oculo-Acoustic Syndrome) Acrocephalopolysyndactyly Type II Acrocephalosyndactyly Type I Acrodysostosis Acrofacial Dysostosis, Nager Type Adams-Oliver Syndrome (see Limb and Scalp Defects, Adams-Oliver Type) Adrenoleukodystrophy, Neonatal (see Cerebro-Hepato-Renal Syndrome) Aglossia Congenita (see Hypoglossia-Hypodactylia) Aicardi Syndrome AIDS Infection (see Fetal Acquired Immune Deficiency Syndrome) Alaninuria (see Pyruvate Dehydrogenase Deficiency) Albers-Schonberg Disease (see Osteopetrosis, Malignant Recessive) Albinism, Ocular (includes Autosomal Recessive Type) Albinism, Oculocutaneous, Brown Type (Type IV) Albinism, Oculocutaneous, Tyrosinase Negative (Type IA) Albinism, Oculocutaneous, Tyrosinase Positive (Type II) Albinism, Oculocutaneous, Yellow Mutant (Type IB) Albinism-Black Locks-Deafness Albright Hereditary Osteodystrophy (see Parathyroid Hormone Resistance) Alexander Disease Alopecia - Mental Retardation Alpers Disease Alpha 1,4 - Glucosidase Deficiency (see Glycogenosis, Type IIA) Alpha-L-Fucosidase Deficiency (see Fucosidosis) Alport Syndrome (see Nephritis-Deafness, Hereditary Type) Amaurosis (see Blindness) Amaurosis
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • Craniosynostosis Precision Panel Overview Indications Clinical Utility
    Craniosynostosis Precision Panel Overview Craniosynostosis is defined as the premature fusion of one or more cranial sutures, often resulting in abnormal head shape. It is a developmental craniofacial anomaly resulting from a primary defect of ossification (primary craniosynostosis) or, more commonly, from a failure of brain growth (secondary craniosynostosis). As well, craniosynostosis can be simple when only one suture fuses prematurely or complex/compound when there is a premature fusion of multiple sutures. Complex craniosynostosis are usually associated with other body deformities. The main morbidity risk is the elevated intracranial pressure and subsequent brain damage. When left untreated, craniosynostosis can cause serious complications such as developmental delay, facial abnormality, sensory, respiratory and neurological dysfunction, eye anomalies and psychosocial disturbances. In approximately 85% of the cases, this disease is isolated and nonsyndromic. Syndromic craniosynostosis usually present with multiorgan complications. The Igenomix Craniosynostosis Precision Panel can be used to make a directed and accurate diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Craniosynostosis Precision Panel is indicated for those patients with a clinical diagnosis or suspicion with or without the following manifestations: ‐ Microcephaly ‐ Scaphocephaly (elongated head) ‐ Anterior plagiocephaly ‐ Brachycephaly ‐ Torticollis ‐ Frontal bossing Clinical Utility The clinical utility of this panel is: - The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. - Early initiation of treatment in the form surgical procedures to relieve fused sutures, midface advancement, limited phase of orthodontic treatment and combined 1 orthodontics/orthognathic surgery treatment.
    [Show full text]
  • Early ACCESS Diagnosed Conditions List
    Iowa Early ACCESS Diagnosed Conditions Eligibility List List adapted with permission from Early Intervention Colorado To search for a specific word type "Ctrl F" to use the "Find" function. Is this diagnosis automatically eligible for Early Medical Diagnosis Name Other Names for the Diagnosis and Additional Diagnosis Information ACCESS? 6q terminal deletion syndrome Yes Achondrogenesis I Parenti-Fraccaro Yes Achondrogenesis II Langer-Saldino Yes Schinzel Acrocallosal syndrome; ACLS; ACS; Hallux duplication, postaxial polydactyly, and absence of the corpus Acrocallosal syndrome, Schinzel Type callosum Yes Acrodysplasia; Arkless-Graham syndrome; Maroteaux-Malamut syndrome; Nasal hypoplasia-peripheral dysostosis-intellectual disability syndrome; Peripheral dysostosis-nasal hypoplasia-intellectual disability (PNM) Acrodysostosis syndrome Yes ALD; AMN; X-ALD; Addison disease and cerebral sclerosis; Adrenomyeloneuropathy; Siemerling-creutzfeldt disease; Bronze schilder disease; Schilder disease; Melanodermic Leukodystrophy; sudanophilic leukodystrophy; Adrenoleukodystrophy Pelizaeus-Merzbacher disease Yes Agenesis of Corpus Callosum Absence of the corpus callosum; Hypogenesis of the corpus callosum; Dysplastic corpus callosum Yes Agenesis of Corpus Callosum and Chorioretinal Abnormality; Agenesis of Corpus Callosum With Chorioretinitis Abnormality; Agenesis of Corpus Callosum With Infantile Spasms And Ocular Anomalies; Chorioretinal Anomalies Aicardi syndrome with Agenesis Yes Alexander Disease Yes Allan Herndon syndrome Allan-Herndon-Dudley
    [Show full text]
  • Back Matter 611-642.Pdf
    Index A Acrodysostosis, 527, 538 Aarskog syndrome, 527, 537 Acrofacial dysostosis 1, 580–581 differentiated from Opitz G/BBB Acrofacial dysplasia, 563 syndrome, 458 Acro-fronto-facio-nasal dysostosis Aase-Smith syndrome, 527 syndrome, 527, 538–539 Aase syndrome, 527, 537 Acromegaloid facial appearance Abducens nerve. See Cranial nerve VI syndrome, 527, 539 Abduction, Möbius sequence-related Acromegaloid phenotype-cutis verticis impairment of, 197, 198 gyrata-cornea leukoma, 527, 539 Abetalipoproteinemia, 527, 537 Acromesomelic dysplasia, Maroteaux- Ablepharon-macrostomia syndrome, Martinelli-Campailla type, 527, 527, 538 539 Abortion, spontaneous, chromosomal Acromicric dysplasia, 527, 539 abnormalities associated with, 83 Acro-osteolysis syndrome, 565 Abruzzo-Erickson syndrome, 527, 538 Acro-reno-ocular syndrome, 527, Acanthosis, 607 539 Acanthosis nigricans, Crouzon Acyclovir, 504, 505, 518 syndrome-related, 169 Adam complex, 207–209 Physician-parent interactions, Adams-Oliver syndrome, 527, 540 69–70 Adduction, Möbius sequence-related Acetyl-coenzyme A deficiency, 364 impairment of, 197, 198 N-Acetylcystine, 321 Adenoma sebaceum, tuberous sclerosis N-Acetyl galactosamine-4-sulfatase complex-related, 304, 308–309 deficiency, 366 Adrenocorticotropic hormone, 433 N-Acetyl galactosamine-6-sulfatase Aging, premature. See also Progeria deficiency, 357, 365 ataxia-telangiectasia-related, 320 a-N-Acetyl glucosaminidase acetyl Aglossia-adactyly syndrome, 584–585 transferase deficiency, 357 Agnathia-holoprosencephaly, 54 a-N-Acetyl glucosaminidase
    [Show full text]
  • BIRTH DEFECTS COMPENDIUM Second Edition BIRTH DEFECTS COMPENDIUM Second Edition
    BIRTH DEFECTS COMPENDIUM Second Edition BIRTH DEFECTS COMPENDIUM Second Edition Editor Daniel Bergsma, MD, MPH Clinical Professor of Pediatrics Tufts University, School of Medicine Boston, Massachusetts * * * M Palgrave Macmillan ©The National Foundation 1973,1979 Softcover reprint of the hardcover 1st edition 1979 978-0-333-27876-5 All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission. First published in the U.S.A. 1973, as Birth Defects Atlas and Compendium, by The Williams and Wilkins Company. Reprinted 1973,1974. Second Edition, published by Alan R. Liss, Inc., 1979. First published in the United Kingdom 1979 by THE MACMILLAN PRESS LTD London and Basingstoke Associated companies in Delhi Dublin Hong Kong Johannesburg Lagos Melbourne New York Singapore and Tokyo ISBN 978-1-349-05133-5 ISBN 978-1-349-05131-1 (eBook) DOI 10.1007/978-1-349-05131-1 Views expressed in articles published are the authors', and are not to be attributed to The National Foundation or its editors unless expressly so stated. To enhance medical communication in the birth defects field, The National Foundation has published the Birth Defects Atlas and Compendium, Syndrome ldentification, Original Article Series and developed a series of films and related brochures. Further information can be obtained from: The National Foundation- March of Dimes 1275 Mamaroneck Avenue White Plains, New York 10605 This book is sold subject to the standard conditions of the Net Book Agreement. DEDICATED To each dear little child who is in need of special help and care: to each eager parent who is desperately, hopefully seeking help: to each professional who brings understanding, knowledge and skillful care: to each generous friend who assists The National Foundation to help.
    [Show full text]
  • ORD Resources Report
    Resources and their URL's 12/1/2013 Resource Name: Resource URL: 1 in 9: The Long Island Breast Cancer Action Coalition http://www.1in9.org 11q Research and Resource Group http://www.11qusa.org 1p36 Deletion Support & Awareness http://www.1p36dsa.org 22q11 Ireland http://www.22q11ireland.org 22qcentral.org http://22qcentral.org 2q23.org http://2q23.org/ 4p- Support Group http://www.4p-supportgroup.org/ 4th Angel Mentoring Program http://www.4thangel.org 5p- Society http://www.fivepminus.org A Foundation Building Strength http://www.buildingstrength.org A National Support group for Arthrogryposis Multiplex http://www.avenuesforamc.com Congenita (AVENUES) A Place to Remember http://www.aplacetoremember.com/ Aarons Ohtahara http://www.ohtahara.org/ About Special Kids http://www.aboutspecialkids.org/ AboutFace International http://aboutface.ca/ AboutFace USA http://www.aboutfaceusa.org Accelerate Brain Cancer Cure http://www.abc2.org Accelerated Cure Project for Multiple Sclerosis http://www.acceleratedcure.org Accord Alliance http://www.accordalliance.org/ Achalasia 101 http://achalasia.us/ Acid Maltase Deficiency Association (AMDA) http://www.amda-pompe.org Acoustic Neuroma Association http://anausa.org/ Addison's Disease Self Help Group http://www.addisons.org.uk/ Adenoid Cystic Carcinoma Organization International http://www.accoi.org/ Adenoid Cystic Carcinoma Research Foundation http://www.accrf.org/ Advocacy for Neuroacanthocytosis Patients http://www.naadvocacy.org Advocacy for Patients with Chronic Illness, Inc. http://www.advocacyforpatients.org
    [Show full text]
  • EUROCAT Syndrome Guide
    JRC - Central Registry european surveillance of congenital anomalies EUROCAT Syndrome Guide Definition and Coding of Syndromes Version July 2017 Revised in 2016 by Ingeborg Barisic, approved by the Coding & Classification Committee in 2017: Ester Garne, Diana Wellesley, David Tucker, Jorieke Bergman and Ingeborg Barisic Revised 2008 by Ingeborg Barisic, Helen Dolk and Ester Garne and discussed and approved by the Coding & Classification Committee 2008: Elisa Calzolari, Diana Wellesley, David Tucker, Ingeborg Barisic, Ester Garne The list of syndromes contained in the previous EUROCAT “Guide to the Coding of Eponyms and Syndromes” (Josephine Weatherall, 1979) was revised by Ingeborg Barisic, Helen Dolk, Ester Garne, Claude Stoll and Diana Wellesley at a meeting in London in November 2003. Approved by the members EUROCAT Coding & Classification Committee 2004: Ingeborg Barisic, Elisa Calzolari, Ester Garne, Annukka Ritvanen, Claude Stoll, Diana Wellesley 1 TABLE OF CONTENTS Introduction and Definitions 6 Coding Notes and Explanation of Guide 10 List of conditions to be coded in the syndrome field 13 List of conditions which should not be coded as syndromes 14 Syndromes – monogenic or unknown etiology Aarskog syndrome 18 Acrocephalopolysyndactyly (all types) 19 Alagille syndrome 20 Alport syndrome 21 Angelman syndrome 22 Aniridia-Wilms tumor syndrome, WAGR 23 Apert syndrome 24 Bardet-Biedl syndrome 25 Beckwith-Wiedemann syndrome (EMG syndrome) 26 Blepharophimosis-ptosis syndrome 28 Branchiootorenal syndrome (Melnick-Fraser syndrome) 29 CHARGE
    [Show full text]
  • Table of Contents
    Table of contents 1 INTRODUCTION........................................................................................................................................... 1 1.1 MEDICAL GENETICSAND THE GENOMIC REVOLUTION.............................................................1 1.2 GENETIC DISORDERS: AN OVERVIEW............................................................................................1 1.3 CONVENTIONAL DIAGNOSTICS AND THE DIAGNOSTIC ODYSSEY....................................... 2 1.4 SANGER AND THE HUMAN GENOME PROJECT...........................................................................3 1.5 THE NEXT-GENERATION-SEQUENCING TECHNOLOGY REVOLUTION................................4 1.6 NGS MODALITIES USED IN THIS STUDY........................................................................................ 5 1.6.1 Whole-Exome Sequencing (WES)..................................................................................................... 5 1.6.2 TruSight™ One Sequencing Panel: “The Mendeliome” ....................................................................6 1.7 AN OVERVIEW OF SYNDROMIC SHORT STATURE SYNDROMES........................................... 7 1.8 THE SKELETAL DYSPLASIAS............................................................................................................8 1.8.1 Osteogenesis Imperfecta.....................................................................................................................9 1.8.1.1 Type I Collagen biosynthesis..................................................................................................10
    [Show full text]